Predictive Tools in Head and Neck Cancer Patients Undergoing Radiotherapy
ITHACA
ITHACA: Development and Validation of a Multivariate Predictive Model for Prognosis in Head and Neck Cancer Patients Undergoing Radiotherapy - Ambispective Study.
1 other identifier
observational
915
1 country
1
Brief Summary
The ITHACA study aims to improve the treatment of head and neck cancer by developing a predictive tool that helps doctors personalize care for each patient. This tool uses information such as medical history, imaging, and radiotherapy data to predict the risk of cancer recurrence, overall survival, and the likelihood of side effects. Patients with head and neck cancer face significant challenges, including managing the side effects of treatments like radiotherapy. By tailoring treatment schedules and doses, and using advanced imaging techniques, we hope to reduce complications and improve survival outcomes. The study is designed to help doctors choose the best treatment for each patient, while minimizing the side effects that impact important functions like swallowing and breathing. Patients participating in the study will have their medical data collected, including: Tumor characteristics (size, location, stage). Treatment details (radiotherapy and chemotherapy). Imaging information using tools like PET-CT and MRI to track the response to treatment and detect any signs of cancer recurrence. Side effects and overall health data. This information will be used to develop and test a new model that predicts outcomes for each patient based on their unique data. The study includes adults (18 years and older) diagnosed with head and neck cancer, who are undergoing or have completed radiotherapy. Patients will be followed over time to monitor their response to treatment and any side effects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedFirst Submitted
Initial submission to the registry
October 21, 2024
CompletedFirst Posted
Study publicly available on registry
February 4, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2034
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2039
February 4, 2025
October 1, 2024
12 years
October 21, 2024
January 31, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cancer Recurrence
The main focus is the probability of recurrence of head and neck cancer after the completion of radiotherapy. This will be assessed at various intervals, specifically at 3, 6, 12, 24, and 36 months post-treatment, using imaging techniques such as PET-CT, MRI, and CT, along with clinical evaluations.
From enrollment to 36 months post-treatment
Interventions
intensity modulated radiotherapy
Eligibility Criteria
This study includes adult patients (≥18 years old) diagnosed with head and neck cancers. Patients are eligible if they are undergoing or scheduled to undergo radiotherapy or chemoradiotherapy in one of the following settings: definitive (primary treatment), adjuvant (post-surgical), or palliative (symptom relief or disease control). The study aims to evaluate treatment effectiveness and monitor side effects across a diverse patient cohort.
You may qualify if:
- Participants must meet all of the following criteria:
- Diagnosis: Confirmed head and neck cancer, including cancers of the oropharynx, larynx, hypopharynx, nasopharynx, salivary gland, unknown head and neck primary or oral cavity.
- Age: 18 years or older.
- Treatment: Undergoing or scheduled to undergo radiotherapy or chemoradiotherapy as part of their treatment
You may not qualify if:
- Participants will be excluded if they meet any of the following criteria:
- Pregnancy: Pregnant or breastfeeding women.
- Non-Compliance: Patients unwilling or unable to comply with study procedures and follow-ups.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, 00168, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mariangela Massaccesi, MD
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 21, 2024
First Posted
February 4, 2025
Study Start
January 1, 2023
Primary Completion (Estimated)
December 31, 2034
Study Completion (Estimated)
December 1, 2039
Last Updated
February 4, 2025
Record last verified: 2024-10